Albion Financial Group’s NovoCure NVCR Stock Holding History

Albion Financial Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,000	Closed	-$60.1K	–	490
2023 Q1	$60.1K	Hold	1,000	–	–	0.01%	205
2022 Q4	$73.3K	Hold	1,000	–	–	0.01%	201
2022 Q3	$76K	Hold	1,000	–	–	0.01%	195
2022 Q2	$70K	Hold	1,000	–	–	0.01%	207
2022 Q1	$83K	Sell	1,000 -15	-1%	-$1.1K	0.01%	236
2021 Q4	$76K	Buy	1,015 +15	+2%	+$1.51K	0.01%	259
2021 Q3	$116K	Hold	1,000	–	–	0.01%	204
2021 Q2	$222K	Buy	+1,000	New	+$195K	0.02%	180
2020 Q4	$173K	Buy	+1,000	New	+$137K	0.02%	189

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Albion Financial Group's NVCR Position: Q2 2023 in Review

Albion Financial Group sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 1,000 shares — an estimated $60.1K sold.

Albion Financial Group first reported a position in NVCR in Q4 2020 and held it in 9 quarters. The position peaked at $222K in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

Albion Financial Group reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
Albion Financial Group sold 1,000 NovoCure shares in Q2 2023, an estimated $60.1K.
Albion Financial Group first reported a position in NovoCure in Q4 2020 and held it in 9 quarters.
Albion Financial Group's NovoCure position peaked at $222K in Q2 2021.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Albion Financial Group's 13F filing for Q2 2023, filed 25 Jul 2023.